Medical devices, healthcare technology and the business of care
510(k) clearance · K261805

NEXT-Cue

Neuroxt, Inc. · Decision date Oct 8, 2026

MEDTECHLEDGER EXPLANATIONK261805

What did the FDA decide?

FDA recorded a substantially equivalent (SESE) decision for NEXT-Cue, a 510(k) submitted by Neuroxt, Inc. of Seoul, KR, under number K261805. The decision date is 2026-10-08; the application was received 06/01/2026. The device is listed under the classification name Prognostic Assessment Software Of Mild Cognitive Impairment, with product code QWT, in the Neurology specialty and Neurology review panel. The submission is a Traditional 510(k), not reviewed by a third party, not a combination product, and without an authorized Predetermined Change Control Plan.

SESE means the submission was cleared as substantially equivalent to a predicate device; it is not a PMA approval. The source page does not identify the predicate device, the specific components or changed items, the intended-use wording, or any performance data supporting the equivalence finding. Those details would sit in the underlying 510(k) review documents rather than the database record summarized here.

No clinical, efficacy or patient-selection conclusions are drawn from this record, and none of the missing elements above should be inferred from the clearance alone.

Regulatory pathway
510(k) premarket notification
Clinical specialty
Neurology
Decision date
Oct 8, 2026
FDA decision documents: 510(k) Premarket Notification - FDA

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
K261805
Regulatory pathway
510(k) premarket notification
Applicant
Neuroxt, Inc.
Product code
QWT
Decision code
SESE
Decision date
Oct 8, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Prognostic Assessment Software Of Mild Cognitive Impairment.

Applicant
Neuroxt, Inc.
Product code
QWT
FDA device class
2

FDA decision timeline

  1. K261805 received

    Application receipt date recorded by FDA.

  2. K261805 · FDA decision

    SESE

Related devices and submissions

Explore the linked device profile

No additional submissions with a verified PMA or product-code relationship are linked here.

Regulatory context

A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Neuroxt, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Seoul

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records